Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.

Molecular cancer research : MCR·2026
Same author

High folate receptor expression is associated with aggressive features in prostate cancer with low prostate-specific membrane antigen expression.

BJUI compass·2026
Same author

Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Characterizing the Activity of Inflammasome-Related Genes and Their Association With Oncological Outcomes in Prostate Cancer.

The Prostate·2026
Same author

Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression.

Bladder cancer (Amsterdam, Netherlands)·2026
Same author

The role of HAI-1 in urothelial bladder cancer: Tissue expression, ectodomain shedding and clinical outcomes.

Biochemistry and biophysics reports·2026

Related Experiment Video

Updated: Jun 27, 2026

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

Diagnostic and prognostic sarcoma signatures.

Elai Davicioni1, Daniel H Wai, Michael J Anderson

  • 1Genome Diagnostics Inc., Pasadena, California, USA.

Molecular Diagnosis & Therapy
|November 28, 2008
PubMed
Summary
This summary is machine-generated.

Molecular expression signatures offer improved diagnosis for sarcomas like rhabdomyosarcoma and Ewing's tumors. These signatures enhance tumor classification and predict treatment response, aiding in better patient outcomes.

More Related Videos

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Related Experiment Videos

Last Updated: Jun 27, 2026

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Area of Science:

  • Oncology
  • Molecular Pathology
  • Genomics

Background:

  • Sarcomas are rare cancers originating from connective tissues, presenting diagnostic challenges due to overlapping histopathology.
  • Accurate diagnosis is crucial for effective sarcoma treatment, as misdiagnosis can lead to suboptimal therapies.
  • Molecular diagnostic approaches are increasingly vital for differentiating sarcoma subtypes.

Purpose of the Study:

  • To review the progress in identifying diagnostic and prognostic gene expression signatures for key sarcomas.
  • To explore the potential of expression signatures in improving sarcoma classification and outcome prediction.
  • To discuss the role of molecular signatures in predicting therapeutic response in sarcoma patients.

Main Methods:

  • Review of current literature on gene expression profiling in sarcomas.
  • Analysis of diagnostic and prognostic expression signatures for rhabdomyosarcoma, Ewing's family of tumors, synovial sarcoma, and osteosarcoma.
  • Discussion of the utility of microarray analysis in tumor discrimination and behavior modeling.

Main Results:

  • Gene expression profiling shows promise in distinguishing sarcoma types and variants more effectively than histology alone.
  • Expression signatures are emerging as powerful tools for predicting patient outcomes and guiding treatment decisions.
  • The reviewed sarcomas (rhabdomyosarcoma, Ewing's, synovial, osteosarcoma) are increasingly benefiting from molecular diagnostic insights.

Conclusions:

  • Gene expression signatures represent a significant advancement in the diagnosis and prognostication of sarcomas.
  • Molecular profiling enhances the precision of tumor classification, leading to more tailored therapeutic strategies.
  • Future research holds potential for further refining expression signatures to optimize sarcoma patient care.